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Abstract
Background: Inhibition of the epidermal growth factor receptor (EGFR) has shown clinical success in patients with advanced
non-small cell lung cancer (NSCLC). Somatic mutations of EGFR were found in lung adenocarcinoma that lead to exquisite
dependency on EGFR signaling; thus patients with EGFR-mutant tumors are at high chance of response to EGFR inhibitors.
However, imaging approaches affording early identification of tumor response in EGFR-dependent carcinomas have so far
been lacking.
Methodology/Principal Findings: We performed a systematic comparison of 39-Deoxy-39-[
18F]-fluoro-L-thymidine ([
18F]FLT)
and 2-[
18F]-fluoro-2-deoxy-D-glucose ([
18F]FDG) positron emission tomography (PET) for their potential to identify response
to EGFR inhibitors in a model of EGFR-dependent lung cancer early after treatment initiation. While erlotinib-sensitive
tumors exhibited a striking and reproducible decrease in [
18F]FLT uptake after only two days of treatment, [
18F]FDG PET
based imaging revealed no consistent reduction in tumor glucose uptake. In sensitive tumors, a decrease in [
18F]FLT PET but
not [
18F]FDG PET uptake correlated with cell cycle arrest and induction of apoptosis. The reduction in [
18F]FLT PET signal at
day 2 translated into dramatic tumor shrinkage four days later. Furthermore, the specificity of our results is confirmed by the
complete lack of [
18F]FLT PET response of tumors expressing the T790M erlotinib resistance mutation of EGFR.
Conclusions: [
18F]FLT PET enables robust identification of erlotinib response in EGFR-dependent tumors at a very early
stage. [
18F]FLT PET imaging may represent an appropriate method for early prediction of response to EGFR TKI treatment in
patients with NSCLC.
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Introduction
Inhibition of the epidermal growth factor receptor (EGFR)
tyrosine kinase by small molecule kinase inhibitors has evolved as a
critical therapeutic strategy in non-small cell lung cancer
(NSCLC). However, only a subset of patients responds to the
treatment; most of these were found to carry activating mutations
in EGFR [1,2,3]. Sensitive methods for mutation detection in
clinical specimens have been developed that enable patient
selection for genetically informed cancer therapy [4,5]. However,
additional patients whose tumors lack EGFR mutations might also
benefit from EGFR inhibitors.
Positron emission tomography using [
18F]FDG PET is an
effective means to staging of NSCLC patients and is now part of
routine staging protocols [6,7]. Furthermore, [
18F]FDG PET has
been found to enable identification of NSCLC patients responding
to chemotherapy [8] and in mice bearing EGFR-mutant tumors
responding to gefitinib [9]. Given that EGFR inhibitor-induced
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e3908apoptosis in EGFR-mutant tumors is preceded by a pronounced
cell cycle arrest [10], we hypothesized that imaging modalities
reflecting tumor cell proliferation rather than glucose metabolism
might afford even earlier measurements of tumor growth
inhibition.
[
18F]-fluoro-L-thymidine ([
18F]FLT) PET has been developed
as a specific marker to measure cellular proliferation in vivo [11]. As
an analog substrate of thymidine, [
18F]FLT is phosphorylated by
thymidine kinase 1 (TK1). TK1 is a cytosolic enzyme that is
synthesized when proliferating cells enter the S-phase for DNA
synthesis [12]. Moreover, [
18F]FLT uptake values have been
shown to correlate to tumor cell proliferation as assessed by Ki-67
immunostaining [13,14]. Thus, [
18F]FLT PET might serve as an
effective means to measure drug-induced cell cycle inhibition in
vivo. Supporting this notion is the recent observation of an
advantage of [
18F]FLT over [
18F]FDG PET in measuring
response of BRAF V600E-mutant melanomas to Mek inhibition
after five days of treatment [15]. Here, we directly compared
[
18F]FDG to [
18F]FLT PET in their ability to measure the
immediate changes in cellular proliferation following inhibition of
a dominant oncogenic signal.
Results and Discussion
As a model of EGFR-dependent NSCLC, we employed the cell
lines HCC827 and PC9. Both cell lines carry mutated as well as
amplified EGFR alleles and are highly sensitive to the EGFR TKI
erlotinib in the low nanomolar range [10]. We used the cell line
H1975 expressing both the L858R mutation of EGFR as well as
the T790M EGFR resistance mutation as a control for specificity
of drug action. After 24h of treatment with even low doses of
erlotinib, sensitive cells were arrested in the G1 phase of the cell
cycle following erlotinib treatment with a concomitant decrease of
cells in the S phase of the cell cycle (Fig. 1A). Subsequent to the
cell cycle arrest the sensitive cell lines PC9 and HCC827
underwent massive apoptotic cell death 36h after onset of
treatment (Fig. 1B). This was paralleled by reduction in p-EGFR
and p-Akt levels in both cell lines (Fig. 1A). By comparison, the
T790M-mutant cell line H1975 showed no cell cycle arrest
(Fig. 1A), no loss of EGFR or Akt phosphorylation (Fig. 1A) and
did not exhibit any signs of apoptotic cell death (Fig. 1B),
confirming that the observed phenotypes were due to on-target
effects of the drug.
We next sought to determine the feasibility of [
18F]FLT and
[
18F]FDG to measure response to erlotinib treatment using a
murine tumor xenograft model. HCC827, PC9 or H1975 cell lines
were individually transplanted subcutaneously onto nude mice.
After oral treatment with either vehicle or erlotinib, mice were
imaged by [
18F]FLT or [
18F]FDG PET. After only 48h of erlotinib
treatment we observed a striking reduction of [
18F]FLT uptake in
the sensitive cell lines HCC827 and PC9. By contrast, no changes
in [
18F]FLT uptake were observed in mice bearing the resistant
cell line H1975 or in the control group treated with the vehicle
alone (Fig. 2A). Quantitative analysis revealed a mean reduction
of [
18F]FLT uptake of 34.6% in the HCC827 xenografts and of
43% in the PC9 xenografts after two days of treatment (p=0.04)
(Fig. 2B). In the resistant H1975 xenografts [
18F]FLT uptake
only slightly decreased by 5.4% (p=0.12) (Fig. 2B). After four
days of erlotinib treatment [
18F]FLT uptake remained decreased
in HCC827 and PC9 tumors whereas we observed no decrease in
[
18F]FLT uptake in the H1975 tumor xenografts. Thus, the
reduction in [
18F]FLT uptake reflects inhibition of cellular
proliferation due to induction of a G1 arrest in EGFR-dependent
tumors.
By comparison, we observed a slight decrease in [
18F]FDG
uptake after 4 days of erlotinib treatment only in the HCC827 but
not in the PC9 xenograft. However, this reduction was far less
pronounced in comparison to the results observed with [
18F]FLT
(Fig. 2B). In a quantitative analysis of these results, the [
18F]FDG
uptake ratios in the PC9 and the HCC827 xenografts were not
significantly decreased after either 2 days or 4 days of treatment
(p=0.13). As expected, H1975 xenografts did not show significant
changes in glucose uptake after either 48 or 96 hours of erlotinib
treatment (Fig. 2B). Thus, in our analysis [
18F]FLT PET
appeared to be superior in detecting response of EGFR-mutant
tumors to EGFR inhibition than [
18F]FDG PET.
We next analyzed cellular proliferation in tumors extracted
from the mice that had undergone PET imaging by Ki-67
staining. On visual microscopic inspection of these tissue
specimens, erlotinib-treated PC9 and HCC827 xenografts but
not H1975 tumors exhibited a substantial reduction in Ki-67
positive cells as compared to the vehicle-treated controls (Fig. 3A
and data not shown). Quantitative analysis revealed that
[
18F]FLT uptake ratios correlated significantly with expression
of Ki-67 (r=0.87, p,0.001, Fig. 3B). By contrast, the
correlation with [
18F]FDG PET was far lower (r=0.38,
p=0.037, Fig. 3B). Thus, [
18F]FLT-based in-vivo measure-
ments of inhibition of proliferation are correlated with in vitro
assessed cellular proliferation.
In order to determine whether our in vitro observation of
apoptosis following cell cycle arrest was reflected in vivo we
analyzed tumor specimens extracted after 4 days of erlotinib
treatment for the presence of apoptotic cells by TUNEL staining.
This analysis revealed the presence of apoptotic cells in the
sensitive cell lines but not in the T790M-carrying tumors (Fig. 3A).
Furthermore, the appearance of apoptotic cells in the sensitive
cells was reflected in dramatic tumor shrinkage starting at day 6 of
treatment (Fig. 3C). Together, these findings show that that a
decrease in [
18F]FLT PET is not only reflective of tumor cells
arrested in G1 but predicts induction of apoptotic cell death and
tumor response in EGFR-addicted tumors treated with erlotinib.
The assessment of therapy response poses a great challenge in
oncology. In particular, the advent of molecularly targeted cancer
therapeutics questions the relevance of conventional morphology-
based response methods such as those defined in the RECIST
criteria [16]. Here, we show that [
18F]FLT PET enables detection
of a therapeutic response in mice receiving erlotinib treatment for
EGFR-mutant lung cancer as early as 48 hours after onset of
treatment. Strikingly, we reliably saw [
18F]FLT PET responses
when morphological changes were still absent and 4 days before
actual tumor shrinkage was observed. The observed responses
were specifically due to inhibition of EGFR kinase activity as mice
with tumors expressing the T790M resistance allele of EGFR did
not exhibit any signs of apoptosis or therapeutic response.
Furthermore, early detection of treatment response was limited
to [
18F]FLT PET. [
18F]FDG PET measurements that had
previously been suggested for this purpose [9] failed in our study
to robustly identify the responding tumors after only two days of
treatment. We suggest that glucose metabolism as assessed by
[
18F]FDG PET rather indirectly reflects tumor cell proliferation
and is therefore not a suitable marker for EGFR inhibition at that
early stage of treatment. Thus, a therapy-induced reduction in
[
18F]FDG PET signal is likely to be a later event, occurring during
actual tumor shrinkage.
In summary, [
18F]FLT PET enables detecting tumor cells
arrested in G1 before morphological changes thereby providing a
surrogate marker for erlotinib-induced apoptosis and tumor
shrinkage at a very early time point. Thus, [
18F]FLT PET might
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PLoS ONE | www.plosone.org 2 December 2008 | Volume 3 | Issue 12 | e3908Figure 1. Erlotinib treatment induces down-regulation of EGFR/EGFR-coupled signaling pathways and cell cycle arrest with
subsequent induction of apoptosis in EGFR sensitive tumor cells. The erlotinib sensitive cell lines HCC827 and PC9 and the erlotinib-resistant
cell line H1975 were treated with the indicated doses of erlotinib for 24 hours. Whole-cell lysates were subjected to immunoblotting with the
indicated antibodies (A). PC9, HCC827 and H1975 cells were treated with erlotinib (0.5 mM) for 24h, 48h and 72h; nuclei were prepared, stained with
propidium iodide and analyzed by flow cytometry. Results are shown for the G1 and S phases of the cell cycle (A). Apoptotic effects of erlotinib on
EGFR-sensitive cell lines in comparison to the T790M mutant H1975 (B). Annexin V FACS was performed 12h, 24h, 36h, 48h, 72h and 96h after 0.5 mM
erlotinib treatment. Images show Annexin V-positive cells after 48h in the different cell lines.
doi:10.1371/journal.pone.0003908.g001
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benefiting from EGFR TKI treatment.
Materials and Methods
Cell cultures
We used the EGFR-tyrosine kinase inhibitor (TKI) sensitive
adenocarcinoma cell lines HCC827, PC9 and the resistant cell line
H1975. All cell lines were maintained in RPMI 1640 supplement-
ed with 10% heat inactivated fetal bovine serum (FBS, Roche
Diagnostics, Mannheim, Germany), 1% penicillin and 1%
streptomycin (P/S, Life Technologies) at 37uC in a 5% CO2/
95% air atmosphere.
Western blot analysis
Cells were serum-starved for 24h in the presence or absence of
erlotinib. After preparation of cell lysates phosphorylation level of
the proteins were determined using antibodies for total EGFR,
phospho-EGFR (pEGFR) (both purchased from Biosource), total
Akt and phospho-Akt (pAKT) (both obtained from Cell Signaling
Technology).
Apoptosis assay
Cells were plated in 6-well plates, after 24h of incubation treated
with erlotinib for 12h, 24h, 36h, 48h, 72h, and 96h and finally
harvested after trypsinization. Then cells were washed with PBS,
resuspended in Annexin-V binding buffer and finally stained with
Annexin-V-FITC and PI. FACS analysis was performed on a
FACS Canto Flow Cytometer (BD Biosciences, Germany) and
results were calculated using FACS Diva Software.
Cell cycle analysis
Cells were fixed and then treated with RNase A (500 mg/ml).
Following resuspension of the cells in propidium iodide and in
sodium citrate cells were analysed for DNA content by flow
cytometry.
Xenograft model
All animal procedures were in accordance with the German
Laws for Animal Protection and were approved by the local
animal committee and the Bezirksregierung Ko ¨ln. Tumors were
generated by s. c. injecting 5610
6 tumor cells into nu/nu athymic
male mice. When tumors had reached a size of 100 mm
3, animals
were randomized into two groups, control (vehicle) and erlotinib-
treated mice. Erlotinib (Tarceva) was dosed at 6% Captisol
(CyDex, Inc., Lenexa, KS) in water for solution over night. All
controls were dosed with the same volume of vehicle. After PET
measurement mice were treated daily by oral gavage of 50mg/kg
Tarceva. Tumor size was monitored every two days by measuring
perpendicular diameters. Tumor volumes were calculated from
the determination of the largest diameter and its perpendicular
according to the equation [tumor volume=a6(b
2/2)].
PET imaging
Tumor bearing mice were investigated using a R4 microPET
scanner (Concord Microsystems, Inc., Knoxville, TN). [
18F]FLT
and [
18F]FDG synthesis were performed as described previously
[17,18]. No-carrier-added [
18F]FLT was administered i.v. (tail
vein) into experimental animals with a dose of 200 mCi/mouse.
No-carrier-added [
18F]FDG was injected intraperitoneally (i.p.)
with a dose of 300 mCi. Since the biodistribution of [
18F]FDG is
Figure 2. [
18F]FLT PET indicates response to therapy after 2 days of erlotinib treatment. In (A) a representative [
18F]FLT PET image of a
mouse bearing the sensitive PC9, HCC827 and the resistant H1975 xenografts before beginning of treatment, 48h and 96h after daily erlotinib
treatment (Tarceva, 50mg/kg). (B) Quantitative analysis of changes in [
18F]FLT and [
18F]FDG uptake ratios after 48h and 96h daily erlotinib treatment
vs. vehicle only as control (PC9: n=8; vehicle, n=2; HCC827: n=7; vehicle, n=2; H1975: n=8; vehicle, n=2).
doi:10.1371/journal.pone.0003908.g002
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injections allow for a more accurate dosage of tracer injection,
we decided to use intraperitoneal injections for [
18F]FDG as
recently described [19,20]. All PET images were performed
60 min after injection. Data evaluation was based on a volume of
interest (VOI) analysis of the entire tumor. For data analysis we
used the maximal voxel radioactivity within the tumors. To
determine the uptake ratio we chose the mediastinum as
reference since we observed constant uptake for [
18F]FLT and
[
18F]FDG in this region. Data were decay corrected and divided
by the total injected dose to represent percentage injected dose
per gram (%ID/g).
Immunohistochemistry and TUNEL detection
After the last PET measurements animals were sacrificed and s.c.
tumors were extracted. After fixation (4% paraformaldehyde, 4uC,
24h; 30% sucrose, 4uC, 24h), tumors were embedded in tissue
freezing medium (Jung, Nussloch, Germany) and cut in 10-mm
frozen sections. H&E staining on the tissue was done according to
standard protocols. Tumor proliferation was assessed using an anti-
Ki-67 monoclonal antibody (1:200 dilution, KI6811C06, DCS,
Hamburg, Germany), and the percentage of specifically stained
cancer cells for Ki-67 was calculated. The number of Ki-67 positive
nuclei wasdeterminedaspercentage of Ki-67stained nuclei per total
number of nuclei in three representative tumor areas ((F1+F2+F3)/3
(%)) that contained the highest average fraction of labelled cells as
described recently [14]. To quantify the number of apoptotic
positive cells TUNEL was performed on cryostat tumor slices with
the DeadEnd
TM TUNEL system (Promega) following the manufac-
turer’s directions. The average numbers of TUNEL positive were
counted in three randomly selected fields in two tumor samples from
each cell line.
Statistical analysis
Wilcoxon test was performed using SPSS software (release
11.0.1 SPSS, Inc., Chicago. IL.USA), statistical significance was
set at p,0.05.
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